Biomarkers - Global Strategic Business Report

The global market for Biomarkers is estimated at US$96.3 Billion in 2023 and is projected to reach US$235.2 Billion by 2030, growing at a CAGR of 13.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth of the biomarker field is driven by several factors. Innovations in detection technologies, such as next-generation sequencing, high-throughput screening, and bioinformatics, have enhanced the precision and speed of biomarker analysis, essential for timely and accurate diagnoses. The integration of biomarkers with artificial intelligence (AI) and big data analytics enables sophisticated data analysis, improving disease pattern prediction and treatment outcomes. In the pharmaceutical industry, biomarkers streamline drug development processes and personalize drug therapies, reducing clinical trial time and costs. Advanced diagnostic platforms that leverage biomarkers offer comprehensive health assessments, enhancing their practical utility in clinical settings. Additionally, rising health awareness and preventive medicine trends influence biomarker adoption, as consumers seek personalized healthcare solutions. Increased consumer participation in healthcare decisions and supportive regulatory frameworks further drive the use of biomarker-based tests and therapies. The expansion of insurance coverage for biomarker tests makes these advanced diagnostics more accessible, embedding biomarkers into routine medical practice and advancing modern medical diagnostics and therapeutic strategies.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Safety Biomarkers segment, which is expected to reach US$89.8 Billion by 2030 with a CAGR of a 13.8%. The Efficacy Biomarkers segment is also set to grow at 12.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $24.9 Billion in 2023, and China, forecasted to grow at an impressive 17.7% CAGR to reach $57.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Biomarkers Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Biomarkers Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Biomarkers Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Abbott Molecular, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 282 Featured):

• Abbott Molecular, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• QIAGEN NV
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.